非小细胞肺癌化疗患者骨髓抑制发生状况及其影响因素

doi:10.3969/j.issn.1000-8535.2023.02.012

摘要/Abstract

摘要： 目的分析非小细胞肺癌化疗患者骨髓抑制发生状况及其影响因素。方法回顾性分析2017年2月—2019年8月期间本院进行化疗治疗的80例非小细胞肺癌患者临床资料,统计非小细胞肺癌化疗患者骨髓抑制发生情况,并根据其情况分组;收集所有患者临床资料,分析非小细胞肺癌化疗患者骨髓抑制发生的相关影响因素。结果 80例非小细胞肺癌化疗患者中发生骨髓抑制45例,发生率为56.25%;经单因素及多项Logistic回归分析,年龄≥60岁、化疗方案为紫杉醇联合铂类,TNM分期在Ⅲ-Ⅳ期,发生骨转移是非小细胞肺癌化疗患者发生骨髓抑制的影响因素(OR＞1,P＜0.05)。结论年龄≥60岁、化疗方案为紫杉醇联合铂类,TNM分期在Ⅲ-Ⅳ期,发生骨转移会增加非小细胞肺癌化疗患者骨髓抑制的发生风险,临床上可据此来制定合理的干预措施,以降低患者骨髓抑制的发生风险。

关键词: 非小细胞肺癌, 化疗, 骨髓抑制

Abstract: Objective To analyze the occurrence and influencing factors of bone marrow suppression in patients with non-small cell lung cancer (NSCLC) undergoing chemotherapy. Methods The clinical data of 80 patients with NSCLC who received chemotherapy in our hospital from February 2017 to August 2019 were retrospectively analyzed, the occurrence of bone marrow suppression in patients with NSCLC under chemotherapy was enrolled and grouped according to the situation; the clinical data of all patients were collected, the related influencing factors of bone marrow suppression in patients were analyzed. Results Among 80 cases of patients with NSCLC, 45 cases occurred bone marrow suppression, the incidence was 56.25%; after univariate and multivariate Logistic regression analysis, age ≥ 60 years old, chemotherapy of paclitaxel combined with platinum, TNM stage in stage III -IV, the occurrence of bone metastasis were the influencing factors of bone marrow suppression in patients with NSCLC under chemotherapy (OR>1, P<0.05). Conclusions Age ≥ 60 years old, chemotherapy of paclitaxel combined with platinum, TNM stage in stage III -IV, the occurrence of bone metastasis will increase the risk of bone marrow suppression in patients with NSCLC chemotherapy. Therefore, reasonable intervention measures can be carried out to reduce the risk.

Key words: non small cell lung cancer, chemotherapy, bone marrow supression

王合法, 闫光辉, 杨召锋. 非小细胞肺癌化疗患者骨髓抑制发生状况及其影响因素[J]. 广州医药, 2023, 54(2): 61-63.

WANG Hefa, YAN Guanghui, YANG Zhaofeng. Occurrence of bone marrow suppression and its influencing factors in patients with non-small cell lung cancer undergoing chemotherapy[J]. Guangzhou Medical Journal, 2023, 54(2): 61-63.

参考文献

[1] 马高磊,王伟,许猛军,等.奈达铂同步放化疗治疗晚期非小细胞肺癌的增敏作用的临床观察[J].中国辐射卫生,2018,27(4):400-402,405.
[2] 许新明,杨健,刘琦,等.宫颈癌调强放疗急性骨髓抑制影响因素分析[J].中华肿瘤防治杂志,2019,26(12):871-875.
[3] 杨利,王骞,陈仙,等.宫颈癌同步放化疗期间骨髓抑制的特点及影响因素分析[J].现代肿瘤医学,2019,27(23):4259-4263.
[4] 高小月,周彩存,顾芬,等.初次确诊非小细胞肺癌患者首次化疗后骨髓抑制危险因素的前瞻性研究[J]同济大学学报(医学版),2018,39(6):102-107.
[5] 胡晓坤,迟焕海,赵淑珍.消化道肿瘤化疗后骨髓抑制期医院感染危险因素分析[J].现代消化及介入诊疗,2017,22(4):472-473.
[6] 王琳,温子禄,朱益军,等.高效抗逆转录病毒治疗联合化疗对HIV合并肺癌患者骨髓抑制和生存质量评分的影响[J].西部医学,2018,30(1):48-51.
[7] 王文.中国高血压基层管理指南(2014年修订版)[J].中国医学前沿杂志(电子版),2015(7):1840.
[8] 张奇兵,袁珺,刘伦波,等.肺癌患者化疗后骨髓抑制45例分析[J].中国医院用药评价与分析,2015,15(12):1662-1664.
[9] 朱青,徐丽华.抗肿瘤药致骨髓抑制的相关因素分析[J].药学与临床研究,2015,23(1):68-70.
[10] 吴建华,梁国华,凌志琴,等.同步放化疗致中晚期宫颈癌患者骨髓抑制发生的危险因素分析[J].实用癌症杂志,2016,31(5):817-819.
[11] 李义秀,陈铭,傅亮,等.71例肿瘤化疗致3~4级骨髓抑制的分析[J].中国医院药学杂志,2018,38(10):1099-1101,1109.
[12] 刘倩欣,向倩,张卓,等.乳腺癌患者化疗药物不良反应情况及影响因素分析[J].中国临床药理学杂志,2018,34(4):475-478.
[13] 张燕芬.429例抗肿瘤药致骨髓抑制的情况分析和防控建议[J].中国医药导刊,2019,21(11):692-694.
[14] 谭燕,张菊.宫颈癌同步放化疗中骨髓抑制的防治进展[J].肿瘤学杂志,2018,24(1):62-66.
[15] 黄维,李英,鲁文力,等.直肠癌同步放化疗所致急性骨髓抑制的临床和物理因素分析[J].中国肿瘤临床,2016,43(16):707-711.
[16] 苏云涛,朱勇,胡志纲,等.放疗联合化疗治疗局限期小细胞肺癌的临床疗效及预后影响因素研究[J].海南医学,2019,30(11):1385-1387.
[17] 石亚飞,陈伟,曹宇,等.非小细胞肺癌患者化疗后骨髓抑制的影响因素分析[J].临床药物治疗杂志,2019,17(11):38-43,61.